as of 11-16-2026 3:59pm EST
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 196.4M | IPO Year: | 2019 |
| Target Price: | $21.50 | AVG Volume (30 days): | 212.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.57 | EPS Growth: | -33.19 |
| 52 Week Low/High: | $5.20 - $17.35 | Next Earning Date: | 11-05-2026 |
| Revenue: | $6,392,000 | Revenue Growth: | 181.46% |
| Revenue Growth (this year): | -75.78% | Revenue Growth (next year): | -56.62% |
| P/E Ratio: | -3.83 | Index: | |
| Free Cash Flow: | -79079000.0 | FCF Growth: | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Director
Avg Cost/Share
$14.30
Shares
40,045
Total Value
$572,643.50
Owned After
121,219
Director
Avg Cost/Share
$15.30
Shares
26,587
Total Value
$400,965.60
Owned After
121,219
10% Owner
Avg Cost/Share
$11.75
Shares
25,124
Total Value
$295,091.43
Owned After
1,624,789
SEC Form 4
10% Owner
Avg Cost/Share
$12.11
Shares
2,510
Total Value
$30,386.31
Owned After
1,624,789
SEC Form 4
10% Owner
Avg Cost/Share
$10.36
Shares
52,175
Total Value
$559,274.17
Owned After
1,624,789
Senior Vice President, Finance
Avg Cost/Share
$13.72
Shares
5
Total Value
$68.58
Owned After
16,241
SEC Form 4
Senior Vice President, Finance
Avg Cost/Share
$13.60
Shares
6
Total Value
$81.62
Owned After
16,241
SEC Form 4
Senior Vice President, Finance
Avg Cost/Share
$13.51
Shares
7,347
Total Value
$99,285.89
Owned After
16,241
SEC Form 4
Director
Avg Cost/Share
$13.96
Shares
300
Total Value
$4,188.00
Owned After
121,219
Director
Avg Cost/Share
$14.00
Shares
28,468
Total Value
$398,552.00
Owned After
121,219
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| FORMELA JEAN FRANCOIS | KRRO | Director | Nov 12, 2026 | Sell | $14.30 | 40,045 | $572,643.50 | 121,219 | |
| FORMELA JEAN FRANCOIS | KRRO | Director | Nov 11, 2026 | Sell | $15.30 | 26,587 | $400,965.60 | 121,219 | |
| Lynx1 Capital Management LP | KRRO | 10% Owner | Oct 26, 2026 | Buy | $11.75 | 25,124 | $295,091.43 | 1,624,789 | |
| Lynx1 Capital Management LP | KRRO | 10% Owner | Oct 23, 2026 | Buy | $12.11 | 2,510 | $30,386.31 | 1,624,789 | |
| Lynx1 Capital Management LP | KRRO | 10% Owner | Oct 22, 2026 | Buy | $10.36 | 52,175 | $559,274.17 | 1,624,789 | |
| Dolan Oliver | KRRO | Senior Vice President, Finance | Sep 11, 2026 | Sell | $13.72 | 5 | $68.58 | 16,241 | |
| Dolan Oliver | KRRO | Senior Vice President, Finance | Sep 9, 2026 | Sell | $13.60 | 6 | $81.62 | 16,241 | |
| Dolan Oliver | KRRO | Senior Vice President, Finance | Sep 8, 2026 | Sell | $13.51 | 7,347 | $99,285.89 | 16,241 | |
| FORMELA JEAN FRANCOIS | KRRO | Director | Aug 26, 2026 | Sell | $13.96 | 300 | $4,188.00 | 121,219 | |
| FORMELA JEAN FRANCOIS | KRRO | Director | Aug 19, 2026 | Sell | $14.00 | 28,468 | $398,552.00 | 121,219 |
SEC 8-K filings with transcript text
Nov 5, 2026 · 100% conf.
1D
-15.04%
$14.12
Act: +2.65%
5D
-25.34%
$12.41
20D
-29.62%
$11.70
2 krro-ex99_1.htm
Exhibit 99.1
Korro Reports Third Quarter 2026 Financial Results and Provides Corporate Update
—
Started dosing healthy volunteers with KRRO-121 in the Phase 1/2 clinical trial (ANCHOR)
o Expect to dose participants with Urea Cycle Disorders (UCDs) in the first half of 2027
o Anticipate reporting interim data in the second half of 2027
—
Achieved best-in-class preclinical data with SERPINA1 mRNA editing (>95%) with KRRO-111
o Planned regulatory submission in the first half of 2027
—
Ended third quarter 2026 with $124.8 million in cash, cash equivalents and marketable securities, supporting a cash runway into the second half of 2028
CAMBRIDGE, Mass., November 5, 2026 – Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today reported results for the third quarter ended September 30, 2026, and provided a corporate update.
“People living with urea cycle disorders face a constant risk of ammonia spikes that can cause lasting neurological harm, even with today’s therapies,” said Ram Aiyar, PhD, MBA, Chief Executive Officer and President of Korro Bio. “Initiating dosing in ANCHOR brings KRRO-121 a meaningful step closer to these patients, and we look forward to dosing participants with UCDs in the first half of 2027. In AATD, our preclinical data showing over 95% correction of the disease-causing transcripts gives us confidence as we prepare KRRO-111 for the clinic. Both programs reflect what our OPERA platform is intended to do: correct disease at the level of RNA, with the precision to generate the protein of interest and convenience of subcutaneous administration. We are focused on execution, with two GalNAc-delivered RNA-editing programs advancing toward clinical data, and a cash runway into the second half of 2028.”
Third Quarter 2026 Highlights and Recent Developments
KRRO-121 in development for hyperammonemia in UCDs and hepatic encephalopathy (HE)
• KRRO-121 is a GalNAc-conjugated RNA-editing oligonucleotide (REO) in development for the potential treatment of hyperammonemia in people living with UCDs or HE
• Dosed the first cohort in ANCHOR (AssessmeNt of Control of Hyperammonemia through Oligonucleotide-based RNA editing), the global Phase 1/2 clinical trial program for KRRO-121 in healthy volunteers and participants with UCD (NCT07773246)
o Part 1: Phase 1 placebo-controlled single ascending dose (SAD) cohorts, followed by multiple ascending dose (MAD) cohorts, evaluating safety, tolerability and pharmacokinetics (PK) in up to 50 healthy volunteers
▪ Participants in the first SAD cohort received either a single 2 mg/kg dose of KRRO-121 or placebo
o Part 2: Phase 2 in a multiple-dose study evaluating safety, tolerability, PK and clinical activity in up to 15 participants with UCDs across genotypes, subject to regulatory clearance to proceed
• Received rare pediatric disease designation from the U.S. Food and Drug Administration (FDA) for KRRO-121 for the treatment of UCDs
KRRO-111 for AATD
• Reported best-in-class preclinical data supporting the potential of KRRO-111 in AATD
• Data from repeat dose-studies in the NSG-Piz mouse model supporting the potential to provide lung benefit include:
o Achieved >95% editing of the SERPINA1 transcripts
o Functional M-AAT made up ~93% of total circulating AAT with total AAT reaching 172μM, approximately six-fold above vehicle at Day 57
• Data from repeat-dose studies in the C57BL/6-PiZ mouse model supporting the potential to provide liver benefit include:
o A near-complete elimination (~95%) of the pathogenic liver Z-AAT
• Together, these preclinical results support the potential of KRRO-111 to address both disease mechanisms in AATD, restoring protective M-AAT targets the lung, and removing toxic Z-AAT aggregates in the liver
Additional Pipeline Programs
• Continued preclinical development of OPERA-derived REOs targeting AMPKγ1 for longevity and TDP-43 for neurodegenerative diseases including amyotrophic lateral sclerosis (ALS)
Participated in healthcare investor conferences and scientific meetings, including:
o the Cantor Global Healthcare Conference
o the Citi 2026 BioPharma Back to School Summit
o the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium
o the XXVI International Roundtable on Nucleosides, Nucleotides and Nucleic Acids (IRT)
o the CNS Summit 2026
o the Oligonucleotide Therapeutics Society (OTS)
Anticipated Milestones over the next 12 months
• KRRO-121: begin dosing participants with UCDs in Part 2 of ANCHOR in the first half of 2027, subject to regulatory clearance to proceed
• KRRO-121: report interim data from ANCHOR in the second half of 2027
• KRRO-111: submit a regulatory application in the first half of 2027
Upcoming Conferences
• BIO-Europe,
Aug 6, 2026 · 98% conf.
1D
+16.49%
$14.12
Act: +9.32%
5D
+48.35%
$17.98
20D
+65.59%
$20.07
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.c706d217.1786061527.e09aced4
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
May 7, 2026 · 100% conf.
1D
-16.74%
$10.73
Act: -5.82%
5D
-27.60%
$9.33
Act: -14.04%
20D
-32.17%
$8.74
Act: -16.83%
SEC.gov | Request Rate Threshold Exceeded
U.S. Securities and Exchange Commission
You’ve Exceeded the SEC’s Traffic Limit
Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.
Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.
The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.
For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.
For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.
Reference ID: 0.c706d217.1784382044.d63096b2
More Information
Internet Security Policy
By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.
Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.
If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.
Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.
Note: We do not offer technical support for developing or debugging scripted downloading processes.
See how KRRO stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "KRRO Korro Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.